UPSC Current Affairs for 29 OCTOBER 2026
Why India rejected a patent application for shorter drug-resistant TB treatment | Explained
India's Patent Office rejected a patent application for the BPaL regimen for drug-resistant TB. This combination offers a shorter treatment duration compared to older regimens lasting 18-24 months.
Economy